Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €3.81 EUR
Change Today +0.015 / 0.40%
Volume 0.0
IM3 On Other Exchanges
As of 10:09 AM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

immunomedics inc (IM3) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/30/15 - €4.75
52 Week Low
05/9/14 - €2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOMEDICS INC (IM3)

immunomedics inc (IM3) Related Bloomberg News

View More Bloomberg News

immunomedics inc (IM3) Related Businessweek News

No Related Businessweek News Found

immunomedics inc (IM3) Details

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases in the United States. Its clinical programs include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; and Yttrium-90 labeled clivatuzumab tetraxetan that is in Phase 3 registration study for the treatment of pancreatic cancer. The company’s antibody-drug conjugate (ADC) products comprise IMMU-132, an ADC that contains SN-38, which is in Phase 2 clinical development focusing on triple-negative breast cancer and colorectal cancer; and IMMU-130, an anti-CEACAM5-SN-38 ADC that is in Phase II clinical development for the treatment of metastatic colorectal cancer. Its early-stage products include Veltuzumab, a humanized monoclonal antibody, which is in Phase 2 study; Milatuzumab, an anti-CD74 antibody for the treatment of graft-versus-host disease that has completed initial Phase 1 studies; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL, which is in Phase 1/2 clinical trial; Milatuzumab-Doxorubicin, a clinically-evaluated agent that is in Phase 1 dose-escalation trial; and IMMU-114, a novel humanized antibody for the treatment of patients with B-cell cancers. The company also provides LeukoScan, a diagnostic imaging product for diagnostic imaging to determine the location and extent of infection/inflammation in bone in patients. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has strategic partnership with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

120 Employees
Last Reported Date: 08/25/14
Founded in 1982

immunomedics inc (IM3) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $618.9K
Founder, Chairman of The Board and Director o...
Total Annual Compensation: $584.5K
Chief Financial Officer and Vice President of...
Total Annual Compensation: $235.5K
Compensation as of Fiscal Year 2014.

immunomedics inc (IM3) Key Developments

Immunomedics Inc. Announces Favorable Results from Lung Cancer Study

Immunomedics Inc. has announced that 33% of patients with small cell lung cancer, or SCLC, and 31% with non-small cell lung cancer, or NSCLC, had their tumor reduced in size by 30% or more, after being treated with sacituzumab govitecan, an investigational antibody-drug conjugate, or ADC. Including patients that reported stable disease as their best response, the ADC controls the progression of the cancer in 75% and 56% of NSCLC and SCLC patients, respectively. These patients had either failed to respond to their last lung cancer therapies or their cancer had returned or progressed. Sacituzumab govitecan is a next generation ADC designed for targeted therapy of solid cancers. The agent was created by site-specifically conjugating a TROP-2-targeting antibody with a high ratio of a moderately toxic drug, SN-38, using a pH sensitive linker. TROP-2 is a receptor found on many human cancer cells, such as cancers of the breast, cervix, colon and rectum, kidney, liver, lung, ovary, pancreas, and prostate, but with only limited expression in normal human tissues. In an animal model of human pancreatic cancer, the ADC delivered up to 135-times the amount of SN-38 to the tumor than when irinotecan, the parent drug of SN-38, was given. A total of 44 heavily-pretreated patients with relapsed or refractory lung cancer have been enrolled into this multicenter study. At the time of analysis, 16 patients with SCLC and 18 with NSCLC were evaluated by computed tomography for response and time-to-progression (TTP). Despite the late-stage setting, TTP for most patients was longer with sacituzumab govitecan than the duration of their previous lung cancer therapy. In the current Phase II study with sacituzumab govitecan, tumor shrinkage was observed in both adenocarcinoma and squamous cell carcinoma. Sacituzumab govitecan continues to produce acceptable safety profile in heavily-pretreated patients, with neutropenia (24% Grades 3 and 4 combined) as the major toxicity. Diarrhea, the typical side effect of irinotecan treatment, was minimal at 3% Grade 3. More importantly, repeated efficacious doses of the ADC can be given to patients over months without evoking any interfering immune response.

Immunomedics Inc. Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014

Immunomedics Inc. reported consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported total revenues of $1,002,791 against $1,202,450 a year ago. Operating loss was $11,461,873 against $8,610,320 a year ago. Loss before income tax expense was $11,438,758 against $8,579,475 a year ago. Net Loss attributable to company’s stockholders was $11,435,235 or $0.12 per basic and diluted share against $8,549,754 or $0.10 per basic and diluted share a year ago. The decrease of $0.2 million in total revenues this quarter was primarily the result of $0.2 million decline in LeukoScan sales volume in Europe. The $2.9 million increase in net loss for the quarter was primarily due to the increase in research and development expenses. For the six months, the company reported total revenues of $2,074,789 against $6,700,271 a year ago. Operating loss was $23,906,007 against $14,166,370 a year ago. Loss before income tax expense was $23,869,557 against $14,123,862 a year ago. Net Loss attributable to company’s stockholders was $23,845,655 or $0.26 per basic and diluted share against $14,073,443 or $0.17 per basic and diluted share a year ago. The $4.6 million decrease in total revenues this period was due to a $4.6 million in license fee revenue earned upon fulfilling the company's obligations under the Algeta Service Agreement, as amended, in the previous year. The $9.7 million increase in net loss this period was primarily due to increased research and development cost related to clinical trials, and higher legal and professional fees in the current period, as well as higher net revenue related to the Algeta agreement in the prior period.

Immunomedics Inc. to Report Q2, 2015 Results on Feb 04, 2015

Immunomedics Inc. announced that they will report Q2, 2015 results on Feb 04, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IM3:GR €3.81 EUR +0.015

IM3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IM3.
View Industry Companies

Industry Analysis


Industry Average

Valuation IM3 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 86.3x
Price/Book 23.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 81.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at